Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 7, Number 2—April 2001
THEME ISSUE
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections
State of the Art

Increasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureus

Fred C. Tenover*, James W. Biddle*, and Michael V. Lancaster†
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Bright Ideas, Monterey, California, USA

Main Article

Table 1

Examples of vancomycin interpretive criteria used internationally

Interpretive criteria for vancomycin (µg/mL)
Organizationa
Susceptible
Intermediate
Resistant
NCCLS <4 8-16 >32
CA-SFM <4 8-16 >32
BSAC <4 ------ >8

aNCCLS, National Committee for Clinical Laboratory Standards; CA-SFM, Comité de l'Antibiogramme de la Société Française Microbiologie; BSAC, British Society for Antimicrobial Chemotherapy.

Main Article

Page created: April 17, 2012
Page updated: April 17, 2012
Page reviewed: April 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external